Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
about
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Targeted Treatment Options in Mastocytosis.Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer.Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy.Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.How we diagnose and treat systemic mastocytosis in adults.Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry.
P2860
Q38661465-734874B1-07C8-45C2-B806-A170A4314944Q41061871-5ADFCF6E-896B-444F-9FD0-8C0B8105621AQ45857609-360CC3A0-E2B0-438F-97E6-47511E2CEAD8Q47113874-A8C37D7B-B310-467C-9F4A-0F1B4C5280FCQ47394090-A0E69102-D5EF-4B51-A27F-1D379AD11A11Q47727992-ABC0501E-5CBB-4E52-8B5F-6952EFB3AD34Q47763014-EF73B354-2256-4310-8A83-F9BC6A866F39Q50091408-8FB01FFC-2F03-485A-8113-C183AA1EDA3BQ52316247-2216CA1F-894D-4359-BDD1-37895CB00CDDQ53681456-09C60619-B6E7-49C0-BBA3-7E121E942434
P2860
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@en
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@nl
type
label
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@en
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@nl
prefLabel
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@en
Masitinib for treatment of sev ...... ebo-controlled, phase 3 study.
@nl
P2093
P2860
P50
P1433
P1476
Masitinib for treatment of sev ...... cebo-controlled, phase 3 study
@en
P2093
Alain Moussy
Christian Auclair
Clive Grattan
Colin Mansfield
Danielle Canioni
Gandhi Damaj
Gérard Guillet
Jean-Pierre Kinet
Julie Agopian
Katia Hanssens
P2860
P304
P356
10.1016/S0140-6736(16)31403-9
P407
P50
P577
2017-01-07T00:00:00Z